



PMI RESEARCH & DEVELOPMENT

Study ZRHR-REXC-03-EU Clinical Study Report Appendix 16.2 CRFs for Deaths, Other Serious Adverse Events, and Withdrawals for Adverse Events

Study Title:	A randomized, controlled, open-label, 3-arm parallel group, single-center study to demonstrate reductions in exposure to selected smoke constituents in smoking, healthy subjects switching to the Tobacco Heating System 2.2 (THS 2.2) or smoking abstinence, compared to continuing to use conventional cigarettes, for 5 days in confinement
Study Number:	ZRHR-REXC-03-EU
Product Name:	Tobacco Heating System 2.2 (THS 2.2)
Study Initiated (first subject screened):	29 June 2013
Study Completed (last subject last visit):	26 September 2013
Principal Investigator and Affiliation:	Katarzyna Jarus-Dziedzic, MD, PhD BioVirtus Research Site Sp. z o.o., Mokra 7 05-830 Kajetany, Poland
Sponsor:	Philip Morris Products S.A. PMI Research & Development Quai Jeanrenaud 5 2000 Neuchâtel, Switzerland
Sponsor Signatories:	Christelle Haziza, PhD, Manager P1 Clinical Program, Clinical Scientist Andrea Donelli, Clinical Scientist Guillaume de La Bourdonnaye, MEng, MSc, Biostatistician Kausar Aamir, MD, PhD, Medical Safety Officer
Version:	4.0
Date:	08 March 2016

This study was conducted in accordance with Good Clinical Practice.

Confidentiality Statement

This document is confidential. Disclosure of any of its contents to third parties is not permitted except by the prior written consent of Philip Morris Products S.A.



TABLE OF CONTENTS

16.2.1 CASE REPORT FORMS FOR SERIOUS ADVERSE EVENTS	3
16.2.2 CASE REPORT FORMS FOR DEATHS	4
16.2.3 CASE REPORT FORMS FOR WITHDRAWALS FOR ADVERSE EVENTS	5



16.2.1 CASE REPORT FORMS FOR SERIOUS ADVERSE EVENTS

Not applicable.



16.2.2 CASE REPORT FORMS FOR DEATHS

Not applicable.



16.2.3 CASE REPORT FORMS FOR WITHDRAWALS FOR ADVERSE EVENTS

Not applicable.